The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1283
Tadalafil (Cialis) Once a Day for Erectile Dysfunction
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The phosphodiesterase type 5 (PDE5) inhibitor tadalafil (Cialis – Lilly) is now being promoted for once-daily treatment of erectile dysfunction. Tadalafil differs from sildenafil (Viagra) and vardenafil (Levitra), the other PDE5 inhibitors marketed for erectile dysfunction in the US, in having a much longer duration of action.1

EFFICACY — The efficacy of taking tadalafil once daily has been demonstrated previously. In one published study, 5 mg once daily was as effective as 10 mg once daily, and both were more effective than placebo.2 In 2 unpublished studies summarized in the package insert, 2.5-mg doses once daily were as effective as 5-mg doses, and both were more effective than placebo.

ADVERSE EFFECTS — The most common adverse effects of PDE5 inhibitors have been headache, facial flushing, nasal congestion and dyspepsia. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Tadalafil (Cialis) Once a Day for Erectile Dysfunction
Article code: 1283c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian